Literature DB >> 34942431

Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy.

Yi Liu1, Leilei Fu1, Junhao Wu2, Ming Liu3, Guan Wang4, Bo Liu5, Lan Zhang6.   

Abstract

In the wake of the development of the concept of cell cycle and its limiting points, cyclin-dependent kinases (CDKs) are considered to play a central role in regulating cell cycle progression. Recent studies have strongly demonstrated that CDKs also has multiple functions, especially in response to extracellular and intracellular signals by interfering with transcriptional events. Consequently, how to inhibit their function has been a hot research topic. It is worth noting that the key role of CDKs in regulating transcription has been explored in recent years, but its related pharmacological targets are less developed, and most inhibitors have not entered the clinical stage. Accordingly, this perspective focus on the biological functions of transcription related CDKs and their complexes, some key upstream and downstream signals, and inhibitors for cancer treatment in recent years. In addition, some corresponding combined treatment strategies will provide a more novel perspective for future cancer remedy.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Biological function; Cancer therapy; Selective transcriptional CDKs inhibitors; Transcriptional CDKs

Mesh:

Substances:

Year:  2021        PMID: 34942431     DOI: 10.1016/j.ejmech.2021.114056

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  4 in total

Review 1.  CDK9 inhibitors in cancer research.

Authors:  Zhi Huang; Tianqi Wang; Cheng Wang; Yan Fan
Journal:  RSC Med Chem       Date:  2022-04-20

2.  Design and Synthesis of Carbothioamide/Carboxamide-Based Pyrazoline Analogs as Potential Anticancer Agents: Apoptosis, Molecular Docking, ADME Assay, and DNA Binding Studies.

Authors:  Manish Rana; Md Imam Faizan; Sajad Hussain Dar; Tanveer Ahmad
Journal:  ACS Omega       Date:  2022-06-23

3.  Selective Cyclin-Dependent Kinase Inhibitors and Their Application in Cancer Therapy.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2022-09-20       Impact factor: 4.632

Review 4.  Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents.

Authors:  Eleni Sflakidou; George Leonidis; Eirini Foroglou; Christos Siokatas; Vasiliki Sarli
Journal:  Molecules       Date:  2022-10-06       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.